Furthermore, we found that the serum levels of BUN and Scr were reduced more profoundly in the therapy group than in the prevention group (Table 1), suggesting that COX-2 inhibitor meloxicam may be used as a therapeutic agent for CKD. The gene discussed is PTGS2; the disease is chronic kidney disease.